- Antibiotics
- Decongestants
- Corticosteroids
- Antihistamines
- Acid Blockers
- Others
Chronic Refractory Cough Market was valued at USD 8982.5 million in 2022 and is poised to grow at a CAGR of 4% over 2023-2029. Chronic refractory cough is defined as a cough that persists despite the guideline-based treatment, and key symptoms include a dry irritated cough localized around the laryngeal region, dyspnea, and dysphonia. Based on the drug class, the combination drugs segment is anticipated to dominate the chronic refractory cough market share over the forecast period. According to an article published in the European Respiratory Journal, the overall prevalence of chronic cough was 9.6%. An increase in the prevalence of conditions such as asthma, bronchitis, GERD, and rising awareness among patients are the chronic refractory cough market growth drivers. However, the side effects associated with the drugs for cough could restrict market growth. Advancements and the use of modern techniques in drug development and diagnosis of the disease could act as opportunities for the players in the market
Chronic Refractory Cough Market Key Developments:
- In June 2022, NeRRe Therapeutics initiated enrolment in a phase-II trial for cough in the USA and UK for Orvepitant.
- In January 2022, Japan’s MHLW approved Merck’s Gefapixant, a selective P2X3 receptor antagonist for the treatment of adults with refractory chronic cough.
Chronic Refractory Cough Market Summary
Study Period
2023-29
Base Year
2022
CAGR
4%
Largest Market
North America
Fastest Growing Market
North America
Chronic Refractory Cough Market Dynamics
Due to rising global healthcare spending and disease awareness, the chronic refractory cough market is expected to witness growth. For instance, the launch of pipeline therapies such as Orvepitant Maleate, BLU-5937, Gefapixant, BAY1817080, and S-600918 will contribute to the market expansion in the upcoming years. Thus, the increased awareness, research, and development for chronic respiratory disorders will lead to the growth of the market within the forecast period. However, the reduced approval rate for drugs will have a negative impact on the market growth.
North-America Got Significant Share of
Chronic Refractory Cough Market Regional Analysis
The chronic Refractory Cough market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. As per the World Health Organization, approximately 235 million people were living with asthma, in 2017. According to the Centers for Disease Control and Prevention data 2019, 1 in every 3 people has asthma, accounting for about 25 million people in the USA. In the Asia Pacific, Middle East, and Africa, chronic disease conditions are on the rise due to rising pollution and infections, i.e., over 60 to 70% of patients in the countries are diagnosed with respiratory diseases, and nearly 30% people are addicted to smoking in these regions. The North America Chronic Refractory Cough market is expected to dominate the market over the forecast period, majorly because of the highly developed healthcare systems in the United States and Canada, as well as the strong presence of major market players, and the rising prevalence and incidence of chronic diseases in the region. Moreover, in the Asia Pacific region, the rise in the patient population and the expansion of products to treat chronic cough with increasing government initiatives to reduce chronic diseases are the major growth factors for the market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The chronic refractory cough market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Chronic Refractory Cough Market Segmentation
By Drug Class
By Route Of Administration
- Oral
- Nasal
- Parenteral
- Others
By End User
- Hospitals
- Clinics
- Homecare
- Others
Frequently Asked Questions
The Chronic Refractory Cough market was valued at USD 8982.5 million in 2022 and is expected to grow at a 4% CAGR over the forecast period 2023 – 2029.
Advancements and the use of modern techniques in drug development and diagnosis of the disease are the key opportunities for the Chronic Refractory Cough market.
An increase in the prevalence of conditions such as asthma, bronchitis, GERD, and rising awareness among patients are the growth drivers in the Chronic Refractory Cough market.
Merck & Co., GSK PLC, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bayer AG, Shionogi Inc., Avalo Therapeutics, Inc., Aldeyra Therapeutics, Axalbion, and Afferent Pharmaceuticals, Inc. are a few companies operating in the Chronic Refractory Cough market.
- Merck & Co.
- GSK PLC
- Kyorin Pharmaceuticals
- NeRRe Therapeutics
- Bayer AG
- Shionogi Inc.
- Avalo Therapeutics, Inc.
- Aldeyra Therapeutics
- Axalbion
- Afferent Pharmaceuticals, Inc.
- Patara Pharma